Peptide Brands Banned on Klaviyo: Why It Happens and the Best Alternatives (2026)

Peptide brands and Klaviyo: the short answer

Klaviyo bans most peptide brands because its Acceptable Use Policy, updated April 9, 2026, prohibits marketing "prescription medications, pharmaceutical products or services, medical therapies, telehealth" and related products. It also reserves the right to restrict anything tied to controlled or illegal substances. Most peptides sold online are unapproved drugs in the eyes of the FDA, so they land squarely inside that ban.

TL;DR

• Why the ban happens: Klaviyo's policy names pharmaceutical products and medical therapies as prohibited. Peptides are treated as drugs, not supplements.
• What triggers enforcement: product names like BPC-157 or semaglutide in emails, dosing language, injection imagery, "research use only" disclaimers, and SMS sent to US carriers.
• What it costs you: suspension can happen without notice, and you may lose your flows, segments and campaign history if you have not exported them.
• What to do instead: move to a sending platform that explicitly accepts your vertical in writing, run email and SMS on separate, compliant infrastructure, and rewrite your messaging so it does not make drug claims.

If you run email or SMS for a peptide, longevity or performance brand, this guide covers what peptides are, the exact reasons Klaviyo shuts these accounts down, and the platforms and setup we use to keep peptide brands sending.

What are peptides?

Peptides are short chains of amino acids, smaller than proteins, that act as signaling molecules in the body. Some are FDA-approved drugs (insulin and GLP-1 medications such as semaglutide are peptides). Many of the ones sold by ecommerce brands, such as BPC-157, TB-500, KPV and MOTS-c, are not approved for any human use.

For marketing purposes, peptide brands usually fall into one of four buckets, and each carries a different level of platform risk:

Where peptide regulation stands in 2026

The rules are moving, but not fast enough to change your email platform's decision. In September 2023 the FDA placed more than a dozen peptides, including BPC-157, in Category 2 of the 503A bulks list, which effectively barred pharmacies from compounding them. On April 15, 2026, HHS removed 12 peptides from Category 2.

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax for the 503A bulks list, on split votes such as 8–6 for BPC-157 (McDermott Will & Schulte). That recommendation is advisory. Formal addition requires notice-and-comment rulemaking that could run into 2027 or later, and even then it would only allow compounding with a valid prescription.

In plain terms: the 2026 changes help compounding pharmacies, not online peptide stores. Selling peptides direct-to-consumer is still treated as selling an unapproved drug, and that is exactly what email and SMS providers screen for.

Why do peptide brands get banned on Klaviyo?

Peptide brands get banned on Klaviyo for five overlapping reasons: the written policy, the controlled-substance clause, SMS carrier rules, the risk Klaviyo's own vendors pass down, and the content of the emails themselves. You only need to trip one.

1. The Acceptable Use Policy names your category

Klaviyo's Acceptable Use Policy lists products and services you may not offer through the platform. The last item covers prescription medications, pharmaceutical products or services, medical therapies, telehealth, and "other related technologies, products, or services." Unapproved injectable peptides, compounded GLP-1s and peptide telehealth programs all fit that description.

2. The controlled and illegal substances clause

The same policy says Klaviyo can evaluate and restrict any use case related to illegal or controlled substances, based on the compliance standards of its downstream providers. That gives Klaviyo room to act even when a peptide is not technically scheduled, because the vendors behind its email and SMS delivery set the bar.

3. SMS carrier rules are stricter than email

For US and Canadian short codes and toll-free numbers, Klaviyo bans SMS content about prescription medication that cannot legally be sold over the counter, plus the SHAFT categories (sex, hate, alcohol, firearms, tobacco). Carriers and the CTIA enforce these rules upstream, so a peptide SMS program can be rejected at registration before a single message goes out. This is why many peptide brands lose SMS first.

4. Shared sending infrastructure means shared risk

Email service providers share sending IPs, domains and carrier relationships across thousands of brands. A high-risk vertical that draws complaints, regulator attention or carrier filtering puts every other customer's deliverability at risk. Platforms protect the pool by removing the vertical, not by judging each brand individually.

5. Your own email content flags you

Accounts are often caught by what they send, not what they sell. The patterns we see most:

• Compound names in subject lines and product blocks (BPC-157, TB-500, semaglutide, tirzepatide)
• Dosing, reconstitution or "protocol" content
• Before-and-after claims about fat loss, healing or recovery
• Vials, syringes and injection imagery
• "Research use only, not for human consumption" disclaimers next to lifestyle copy that implies human use
• Spikes in spam complaints after importing a list from a previous platform

The "research use only" label is the most common misconception. It does not move a product out of the pharmaceutical category, and pairing it with consumer-facing copy reads as evidence that the label is a workaround.

What happens when Klaviyo suspends a peptide brand?

Klaviyo's policy lets it suspend, terminate or limit an account immediately, at its sole discretion, and without liability to you. In practice that means sending stops first and questions come later.

Warning signs before a ban

• SMS registration is rejected or stuck in review
• An account review email asking you to describe your products
• Campaigns held in a "sending paused" or compliance review state
• A sudden drop in inbox placement or a jump in spam complaints after a peptide launch

What you can lose

• Revenue flows: welcome, abandoned cart, browse abandonment and post-purchase flows stop the moment sending is paused. For most ecommerce brands, these drive the majority of email revenue.
• Data access: if you have not exported profiles, consent timestamps, segments and templates, recovering them after termination can be slow or incomplete.
• SMS consent records: proof of opt-in is what makes a list portable. Without timestamps and source data, you may not be able to legally message those subscribers from a new platform.

Can you appeal?

You can contact support, but if your products fall inside the prohibited categories, an appeal rarely changes the outcome. Opening a new account under a different brand or domain to keep sending is also a policy violation: Klaviyo prohibits snowshoeing across domains and misrepresenting your sender identity. The durable fix is a platform that accepts your vertical.

Best Klaviyo alternatives for peptide brands in 2026

The best Klaviyo alternative for a peptide brand is a platform that accepts your product category in writing, not just one with similar features. In 2026, several mainstream platforms name peptides as banned outright, so switching from Klaviyo to another big ESP often just restarts the clock on your next suspension.

Platforms to avoid: written policies that block peptides

Options that can work

Whichever route you pick, ask for one thing before you sign: an email from the vendor confirming your exact products and site URL are approved. A sales rep's verbal "we work with brands like you" is not protection when compliance reviews your account later.

What about SMS for peptide brands?

SMS is the hardest channel to keep. US carrier and CTIA rules, enforced through every SMS provider, block content about prescription drugs that cannot be sold over the counter, and that restriction follows you from Klaviyo to any other platform. For injectable, research-use or compounded peptides, plan on running without promotional SMS in the US and lean on email, owned community channels and transactional order updates instead. Cosmetic peptide brands with clean copy have a much better chance of registration approval.

How to migrate off Klaviyo without losing your list

Migrate in this order: export everything, lock in written approval, authenticate and warm a new domain, then rebuild revenue flows before campaigns. Most of the revenue loss in a forced migration comes from skipping the warm-up and blasting the full list on day one.

1. Export before anything else. Pull all profiles with consent status, opt-in date and source, plus suppressed and unsubscribed contacts. Export segments, flow logic, templates and 12 months of campaign performance. Unsubscribes must travel with you so nobody who opted out is emailed again.
2. Get category approval in writing. Send the new vendor your product list and site URL and keep their written confirmation on file.
3. Set up a fresh sending domain. Use a subdomain (for example, mail.yourbrand.com) with SPF, DKIM and DMARC configured, and enable one-click unsubscribe. Do not reuse a domain that just generated complaints.
4. Warm up gradually. Start with customers who opened or clicked in the last 30 days, then widen to 60 and 90 days over several weeks. Hold back cold and unengaged contacts until inbox placement is stable.
5. Rebuild revenue flows first. Welcome, abandoned cart, browse abandonment and post-purchase flows go live before your first campaign. They are triggered by engaged visitors, so they also help warm the domain.
6. Rewrite as you rebuild. Do not paste old Klaviyo copy into the new platform. Strip drug claims and dosing language before anything sends (see the checklist below).
7. Monitor weekly. Track spam complaint rate, hard bounces and inbox placement for the first 60 days. Google and Yahoo bulk-sender rules expect complaint rates below 0.3%, and the safest programs stay under 0.1%.

Compliance checklist: how peptide brands avoid the next ban

A new platform only buys you time if the program itself stays clean. Run every email and SMS through this list before it sends.

• No disease, healing, fat-loss or performance claims ("heals tendons", "melts fat", "boosts growth hormone")
• No dosing, reconstitution, injection or "protocol" instructions
• No syringes, injection imagery or before-and-after photos
• No compound names in subject lines or preheaders
• Lifestyle copy never sits next to a "research use only" disclaimer
• Every contact has a recorded opt-in with date and source; no purchased or scraped lists
• One-click unsubscribe in every marketing email; STOP handling in every SMS
• SPF, DKIM and DMARC pass on the sending domain
• Spam complaints tracked weekly and kept under 0.1%
• Written category approval from your platform saved where the whole team can find it
• Copy reviewed against current FDA and FTC rules by someone qualified; claims rules change as the 503A rulemaking moves

The FTC requires health claims to be backed by competent and reliable scientific evidence, and that applies to your emails as much as your product pages. This checklist is marketing guidance, not legal advice.

Frequently asked questions

Does Klaviyo allow peptide brands?

No, not for most peptide brands. Klaviyo's Acceptable Use Policy prohibits marketing prescription medications, pharmaceutical products, medical therapies and telehealth. Injectable, research-use and compounded peptides fall inside those categories. Cosmetic peptide skincare with no drug claims is generally treated differently.

Why was my Klaviyo account suspended for selling peptides?

Klaviyo can suspend accounts immediately if it decides your products or content violate its policy. For peptide brands, the usual triggers are the product category itself, compound names and dosing language in emails, injection imagery, and SMS content that breaks US carrier rules.

Does a "research use only" label make peptides allowed on Klaviyo?

No. Platforms judge what you sell and how you market it, not the disclaimer. Brevo's policy, for example, specifically says peptide products labeled "research use only" are not accepted.

What is the best Klaviyo alternative for peptide companies?

The best alternative is a platform that confirms your exact products in writing. Options include peptide-specific platforms such as Amino Engine, ecommerce ESPs such as Sendlane once they approve your category in writing, or self-hosted sending on infrastructure you control. Avoid Brevo, SMTP2GO and Elastic Email, whose policies prohibit peptides or pharmaceuticals.

Can peptide brands use SMS marketing?

Rarely in the US. Carrier and CTIA rules block promotional SMS about prescription drugs that cannot be sold over the counter, and those rules apply on every SMS platform. Most injectable or research peptide brands should treat promotional SMS as unavailable and focus on email.

Did the FDA make BPC-157 legal in 2026?

Not yet. In July 2026 an FDA advisory committee voted to recommend BPC-157 and five other peptides for the pharmacy compounding list. The recommendation is advisory, formal rulemaking is still pending, and even then it would only allow compounding with a prescription. Direct-to-consumer sales remain a high-risk category for email platforms.

Will I lose my email list if Klaviyo bans me?

You keep the right to your subscribers, but you can lose access to the data if you have not exported it. Export profiles, consent records, unsubscribes and suppression lists regularly while your account is in good standing.

Get your peptide brand sending again

We're an email and SMS agency for ecommerce brands, and peptide and longevity brands are a category we know well. If Klaviyo has paused or banned your account, we'll help you export your data, pick a platform that approves your category in writing, warm up a new domain and rebuild the flows that drive most of your email revenue, with compliant copy from day one.

Book a free Klaviyo ban recovery call →

Sources

• Klaviyo Acceptable Use Policy (updated April 9, 2026)
• Klaviyo: SMS and MMS prohibited content
• Brevo Acceptable Use Policy
• SMTP2GO contract terms
• Omnisend Acceptable Use Policy
• Elastic Email Acceptable Use Policy
• Amino Engine: Mailchimp alternative for peptide brands (quotes Mailchimp's policy)
• McDermott Will & Schulte: PCAC backs majority of peptides (July 27, 2026)
• FTC: Health claims guidance